Combination Product Technology to Reach $31 Billion; Sector Attracting Massive Developmental Companies

BCC Research reveals in its new report on drug-device combination products, developments in cell-based therapeutics, progenitor cell exploitation, growth factor delivery, and advanced formulation strategies are becoming the basis of even more advanced combination device strategies. Technology advancements in the drug-device combination market have been of considerable importance in recent years, and the pace of activity seems to be quickening with the appearance of many development-stage companies. The overall market is growing at a compound annual growth rate (CAGR) of 7.1% from 2014 to 2019, and thus sales are projected to reach $31 billion in 2019.

​

The development of the market for combination products is closely related to another dynamic and fast-growing healthcare segment generally termed drug delivery systems. Delivery systems represent a vast area of research, and the demand for sophisticated drug delivery devices is behind many novel product developments. Advanced drug delivery devices offer increased efficiency, improved performance, and convenience.

“The combination product industry is growing relatively rapidly, with particular dynamism in successful niche products. It is attracting a lot of startup capital for research and development (R&D) and developmental companies,” says BCC Research analyst Kevin Gainer. “Established products, such as drug-eluting stents, anti-microbial catheters, and photodynamic therapy, represent fairly large markets.”

It is anticipated that combination products will enable the use of therapy candidates that cannot currently be used alone due to systemic effects and toxicities. Combination product technology will enable safer and more effective technologies due to careful and precise drug targeting, local administration, and individualized therapy. These have paved the way for combination products that will help patients suffering from cancer, heart disease, multiple sclerosis, cerebral palsy, spinal-cord injuries, anemia, hepatitis, rheumatoid arthritis, diabetes, and other serious diseases and conditions.

The number and technological import of patents relating to products in this industry reflect the enormous efforts and expenditures to develop breakthrough therapies for serious human diseases.

Global Markets for Drug-Device Combinations analyzes the market for drug-device combination products. It provides review of technologies and products, status of R&D initiatives, and a forecast of market revenues through 2019. Company profiles, clinical trials, and a patent analysis are provided as well.

BCC Research publishes market research reports that make organizations worldwide more profitable with intelligence that drives smart business decisions. These reports cover today’s major industrial and technology sectors, including emerging markets. For more than 40 years the company has helped customers identify new market opportunities with accurate and reliable data and insight, including market sizing, forecasting, industry overviews, and identification of significant trends and key market participants. It partners with analysts who are experts in specific areas of industry and technology, providing unbiased measurements and assessments of global markets. Recently selected as the world’s greatest market research company, BCC Research is a unit of Eli Global, LLC. Visit the website at www.bccresearch.com. Contact: (+1) 781-489-7301 (U.S. Eastern time), or email information@bccresearch.com.

​